Lilly Announces Updated Verzenio (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology
Adjuvant Verzenio in combination with endocrine therapy (ET) continued to demonstrate a significant improvement in reducing the risk of recurrence in patients with HR+ HER2-, node-positive, high risk early breast cancer
With additional follow up, the treatment benefit of Verzenio plus ET was maintained over time and extended beyond the two-year treatment period; mature safety analysis was also consistent with previous results
Consistent Verzenio treatment benefit in reducing risk of recurrence observed in patients regardless of Ki-67 score
Primary Outcome1 |
Additional Follow-Up |
|||
Data cut-off date |
July 8, 2020 |
April 1, 2021 |
||
Patients off study treatment period |
41.0% |
89.6% |
||
?????Efficacy Results |
Verzenio + ET |
ET alone |
Verzenio + ET |
ET alone |
Median follow-up, months |
19.1 |
27.1 |
||
Invasive disease-free survival (IDFS) |
||||
Events, n |
163 |
232 |
232 |
333 |
IDFS rates, % (95% CI) |
||||
2-year |
92.3 (90.9, 93.5) |
89.3 (87.7, 90.7) |
92.7 (91.6, 93.6) |
90.0 (88.8, 91.1) |
3-year |
Not estimable |
Not estimable |
88.8 (87.0, 90.3) |
83.4 (81.3, 85.3) |
HR (95% CI) p-value |
0.71 (0.58, 0.87) *Nominal p-value =?0.0009 |
0.70 (0.59, 0.82) *Nominal p-value <0.0001 |
||
Distant relapse-free survival (DRFS) |
||||
Events, n |
131 |
193 |
191 |
278 |
DRFS rates, % (95% CI) |
||||
2-year |
93.8 (92.6, 94.9) |
90.8 (89.3, 92.1) |
94.1 (93.2, 95.0) |
91.6 (90.5, 92.6) |
3-year |
Not estimable |
Not estimable |
90.3 (88.6, 91.8) |
86.1 (84.2, 87.9) |
HR (95% CI) |
0.69 (0.55, 0.86) |
0.69 (0.57, 0.83) |
||
1?Johnston SRD, Harbeck N, Hegg R, et al; monarchE Committee Members and Investigators. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE) [published online ahead of print, September 20, 2020].?J Clin Oncol. doi:10.1200/JCO.20.02514. |
||||
*The primary efficacy endpoint was statistically significant at interim analysis 2 |
Verzenio + ET |
ET alone |
HR (95% CI) |
|
Cohort 1 Ki-67 High, N = 2003 |
|||
Patients, N |
1017 |
986 |
0.626 (0.488, 0.803) |
Events, n |
104 |
158 |
|
3-Year IDFS Rates |
86.1% |
79.0% |
|
Cohort 1 Ki-67 Low, N = 1914 |
|||
Patients, N |
946 |
968 |
0.704 (0.506, 0.979) |
Events, n |
62 |
86 |
|
3-Year IDFS Rates |
91.7% |
87.2% |
*Data from Additional Follow-up analysis with a data cut-off date of April 1, 2021 |
monarchE?is a global, randomized, open-label, two cohort, multicenter Phase 3 study in adult women and men with HR+ HER2-, node-positive resected EBC with clinical and pathological features consistent with a high risk of disease recurrence. A total of 5,637 patients were randomized (1:1) to receive two years of Verzenio 150 mg twice daily plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Patients in both treatment arms were instructed to continue to receive adjuvant endocrine therapy for up to 5-10 years as recommended by their clinician. Cohort 1 enrolled patients with =4 positive axillary lymph nodes (ALN), or 1-3 positive ALN and either Grade 3 disease or tumor size =5 cm. Cohort 2 enrolled patients with 1-3 positive ALN and centrally determined Ki-67 score of =20%. The primary endpoint was IDFS in the ITT population (Cohorts 1 & 2). Secondary endpoints were IDFS in patients with high Ki-67 score (in the ITT population and in the Cohort 1 population), DRFS, overall survival, and safety.1,2 About Early Breast Cancer and Risk of Recurrence
It is estimated that 90 percent of all breast cancers are detected at an early stage. Although the prognosis for HR+ HER2- EBC is generally positive, 20 percent of patients will experience recurrence potentially to incurable metastatic disease.3?Risk of recurrence is greatest within the initial two to three years post-diagnosis, particularly in patients with node-positive, high risk EBC.4?Factors associated with high risk of recurrence include: positive nodal status, large tumor size (=5 cm), high tumor grade (Grade 3), and high rate of cellular proliferation [Ki-67 score (=20%)].2 Node-positive means that cancer cells from the tumor in the breast have been found in the lymph nodes in the armpit area. Although the breast cancer is removed through surgery, the presence of cancer cells in the lymph nodes signifies that there is a higher chance of the cancer returning and spreading. About Breast Cancer
Breast cancer has now surpassed lung cancer as the most commonly diagnosed cancer worldwide, according to GLOBOCAN. The estimated 2.3 million new cases indicate that 1 in every 8 cancers diagnosed in 2020 is breast cancer. With approximately 685,000 deaths in 2020, breast cancer is the fifth-leading cause of cancer death worldwide.5?In the U.S., it is estimated that there will be 281,550 new cases of breast cancer in 2021.6 Approximately 70 percent of all breast cancers are of the HR+ HER2- subtype.6 About Verzenio? (abemaciclib)
Verzenio??abemaciclib is a targeted treatment known as a CDK4/6 inhibitor. Verzenio is a non-chemotherapy oral tablet. Verzenio works inside the cell to block CDK4/6 activity and help stop the growth of cancer cells, so they may eventually die (based on preclinical studies).* Cyclin-dependent kinases (CDK)4/6 are activated by binding to D-cyclins. In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4/6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation. In vitro, continuous exposure to Verzenio inhibited Rb phosphorylation and blocked progression from G1 to S phase of the cell cycle, resulting in senescence and apoptosis (cell death). Preclinically, Verzenio dosed daily without interruption resulted in reduction of tumor size. Inhibiting CDK4/6 in healthy cells can result in side effects, some of which may be serious. Clinical evidence also suggests that Verzenio crosses the blood-brain barrier. In patients with advanced cancer, including breast cancer, concentrations of Verzenio and its active metabolites (M2 and M20) in cerebrospinal fluid are comparable to unbound plasma concentrations. Verzenio is Lilly's first solid oral dosage form to be made using a faster, more efficient process known as continuous manufacturing. Continuous manufacturing is a new and advanced type of manufacturing within the pharmaceutical industry, and Lilly is one of the first companies to use this technology. INDICATIONS FOR VERZENIO Verzenio??(abemaciclib) in combination with endocrine therapy (ET) is indicated for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at high risk of recurrence and a Ki-67 score of =20% as determined by an FDA-approved test. Verzenio is indicated for the treatment of HR+ HER2- advanced or metastatic breast cancer:
- in combination with an aromatase inhibitor for postmenopausal women, and men, as initial endocrine-based therapy
- in combination with fulvestrant for adult patients with disease progression following endocrine therapy
- as a single agent for adult patients with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting
Share this article on WhatsApp, LinkedIn and Twitter
Incisive News in 3 Shots.
Contact Us
- First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
- +91-120 428 0707
- connect@pharmashots.com
- Newsletter
Our Information
Modal title
Modal body text goes here.